Literature DB >> 10094975

Human leukocyte antigen class II and III alleles and severity of hepatitis C virus-related chronic liver disease.

M Asti1, M Martinetti, C Zavaglia, M C Cuccia, L Gusberti, C Tinelli, A Cividini, S Bruno, L Salvaneschi, G Ideo, M U Mondelli, E M Silini.   

Abstract

Hepatitis C outcome is likely related both to viral factors and host's immune responses. We correlated the severity of liver disease with human leukocyte antigen (HLA) genes (C4A, C4B, TNFA, TNFB, DRB1, DRB3, DRB4, DRB5, DQA1, DQB1, TAP1, and TAP2) in three groups of subjects: 99 patients with chronic hepatitis, 41 asymptomatic carriers, and 179 uninfected controls. Patients with grade/stage 3 to 4 hepatitis significantly differentiated for their low frequency of alleles TNFB*1, DRB1*1104, and DRB3*03, which had a protective role, and high frequency of allele DRB1*1001, which was associated with disease severity. HLA-DRB*11 subtypes were differentially distributed: DRB1*1104 was most frequent in carriers, whereas DRB1*1101 was more frequent in patients. The TAP1C,2A haplotype was also underrepresented in patients with respect to controls. Finally, a decrease of heterozygous subjects was observed in patients with respect to carriers at the DQB1 locus. Multivariate analysis by correspondence analysis and multiple logistic regression indicated that age, sex, and hepatitis C virus (HCV) type were the strongest risk factors; however, some immunogenetic variables (TNFB*1, DRB1*1104, and DRB3*03) showed an independent contribution, especially in comparing patients with extreme manifestations of disease. The involvement of different genes in various HLA subregions suggests that anti-HCV responses are modulated by a complex gene interplay rather than by single alleles.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10094975     DOI: 10.1002/hep.510290445

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  13 in total

1.  Low frequency of HLA-DRB1*11 in hepatitis C virus induced end stage liver disease.

Authors:  H L Tillmann; D F Chen; C Trautwein; V Kliem; A Grundey; A Berning-Haag; K Böker; S Kubicka; L Pastucha; W Stangel; M P Manns
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

2.  Clinical Monitoring of Chronic Hepatitis C Based on its Natural History and Therapy.

Authors:  Douglas L Nguyen; Ke-Qin Hu
Journal:  N Am J Med Sci (Boston)       Date:  2014

3.  A specific gene-expression signature quantifies the degree of hepatic fibrosis in patients with chronic liver disease.

Authors:  Tohru Utsunomiya; Masahiro Okamoto; Shigeki Wakiyama; Masaji Hashimoto; Kengo Fukuzawa; Takahiro Ezaki; Shinichi Aishima; Yasuji Yoshikawa; Taizo Hanai; Hiroshi Inoue; Graham-F Barnard; Masaki Mori
Journal:  World J Gastroenterol       Date:  2007-01-21       Impact factor: 5.742

4.  Histological features and HLA class II alleles in hepatitis C virus chronically infected patients with persistently normal alanine aminotransferase levels.

Authors:  C Renou; P Halfon; S Pol; P Cacoub; E Jouve; J P Bronowicki; J P Arpurt; H Rifflet; M Picon; X Causse; V Canva; J Denis; A Tran; M Bourliére; D Ouzan; A Pariente; S Dantin; L Alric; V Cartier; M Reville; S Caillat-Zucman
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

5.  Genetic variants in the CCR gene cluster and spontaneous viral elimination in hepatitis C-infected patients.

Authors:  S Mascheretti; H Hinrichsen; S Ross; P Buggisch; J Hampe; U R Foelsch; S Schreiber
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

6.  Association between HLA class II gene and susceptibility or resistance to chronic hepatitis B.

Authors:  Ye-Gui Jiang; Yu-Ming Wang; Tong-Hua Liu; Jun Liu
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

Review 7.  Managing occupational risks for hepatitis C transmission in the health care setting.

Authors:  David K Henderson
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

Review 8.  Host genetic factors and antiviral immune responses to hepatitis C virus.

Authors:  Chloe L Thio
Journal:  Clin Liver Dis       Date:  2008-08       Impact factor: 6.126

Review 9.  A comparative review of HLA associations with hepatitis B and C viral infections across global populations.

Authors:  Rashmi Singh; Rashmi Kaul; Anil Kaul; Khalid Khan
Journal:  World J Gastroenterol       Date:  2007-03-28       Impact factor: 5.742

Review 10.  Thyroid disease in chronic hepatitis C infection treated with combination interferon-α and ribavirin: management strategies and future perspective.

Authors:  Huy A Tran; Tracey L Jones; Elizabeth A Ianna; Aidan Foy; Glenn E M Reeves
Journal:  Endocr Pract       Date:  2013 Mar-Apr       Impact factor: 3.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.